

Clinical Trial Protocol

Iranian Registry of Clinical Trials

10 Jun 2026

The effects of PRP with reduced Leukocyte content therapy on chronic knee osteoarthritis

Protocol summary

Study aim

The effects of PRP with reduced Leukocyte content therapy on chronic knee osteoarthritis

Design

This study is single-blind, phase 2 clinical trials on 15 patients based on inclusion and exclusion criteria, the study procedure will be explained to patients, and informed consent will be obtained before the study. One knee will be randomly selected for leukocyte-rich PRP injection and another knee will be injected using PRP with reduced Leukocyte content.

Settings and conduct

Initially, the following items will be recorded for the patients who meet the inclusion criteria: Pain by VAS, Knee function by WOMAC, Knee function by KOOS, Flexion range of motion. After PRP preparation, patients will be referred to the Rehabilitation Department of the Shahid Madani Hospital. PRP injection will be given to patients supralaterally. The injection will be repeated twice with a 21 days apart. Then, the effect of PRP on patients will be evaluated in the intervals of 1, 3 and 6 months after the first injection.

Participants/Inclusion and exclusion criteria

Radiologic findings with a period of three-month symptoms of knee osteoarthritis in both of knees. No history of knee surgery, blood disorders and confounders in the study results and no extraordinary deformation

Intervention groups

PRP with reduced Leukocyte content Treatment group, Control group: treatment with Leukocyte-rich PRP.

Main outcome variables

1- Determining knee pain by VAS in all phases of clinical trial 2-Determination of knee function by WOMAC and KOOS in all phases of clinical trial 3-Determine the range of knee motion by manual jointometry in all phases of the trial

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20160422027520N14**

Registration date: **2019-08-24, 1398/06/02**

Registration timing: **registered_while_recruiting**

Last update: **2019-12-30, 1398/10/09**

Update count: **1**

Registration date

2019-08-24, 1398/06/02

Registrant information

Name

Mehdi Yousefi

Name of organization / entity

Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

Country

Iran (Islamic Republic of)

Phone

+98 41 3336 4665

Email address

yousefime@tbzmed.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2019-08-23, 1398/06/01

Expected recruitment end date

2020-03-19, 1398/12/29

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

The effects of PRP with reduced Leukocyte content therapy on chronic knee osteoarthritis

Public title

Treatment of chronic knee osteoarthritis with PRP with reduced Leukocyte content

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

Men and women between the ages of 18 and 75 with OA diagnosis based on the American College of Rheumatology Analog scale of knee pain (VAS) equal to or greater than 2.5 People with at least 4 months of history of pain or swelling in one or both knees Radiological classification scale Kellgren-Lawrence 1 or 2 The availability of individual during the study period BMI Between 20 and 35

Exclusion criteria:

People under the age of 18 and over 75 years Pregnant women or women who are breastfeeding People with malignancy, People with severe heart disease, uncontrolled diabetes mellitus, rheumatoid arthritis, hemorrhagic diseases, history of anemia, arthritis, fibromyalgia and chronic fatigue syndrome People with acetaminophen or vicodin addiction or a history of drug misuse History of cortisone injections in the last 6 weeks The use of non-steroidal anti-inflammatory drugs 1 week ago Having hemoglobin less than 11 g / dl and platelet count less than 150000 / m μ The use of inhibitors of platelet aggregation and anti-coagulation such as heparin History of knee surgery in the last 3 months Extraordinary deformation (varus >5°, valgus >5°)

Age

From **18 years** old to **75 years** old

Gender

Both

Phase

2

Groups that have been masked

- Participant

Sample size

Target sample size: **15**

Randomization (investigator's opinion)

Not randomized

Randomization description

Blinding (investigator's opinion)

Single blinded

Blinding description

The study participant will be unaware of his placement in the study group (PRP with reduced Leukocyte content or Leukocyte-Rich PRP).

Placebo

Not used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics committee of Tabriz University of Medical Sciences

Street address

Tabriz University of Medical Sciences , Daneshgah st, Tabriz,

City

Tabriz

Province

East Azarbaijan

Postal code

5166614766

Approval date

2019-07-29, 1398/05/07

Ethics committee reference number

IR.TBZMED.REC.1398.472

Health conditions studied

1

Description of health condition studied

Osteoarthritis

ICD-10 code

M15.4

ICD-10 code description

Erosive (osteo)arthritis

Primary outcomes

1

Description

Determining knee pain

Timepoint

Before injection and 1, 3 and 6 months after the first injection

Method of measurement

Questionnaire (VAS)

2

Description

Determination of knee function

Timepoint

Before injection and 1, 3 and 6 months after the first injection

Method of measurement

Questionnaire (WOMAC), Questionnaire (KOOS)

3

Description

Determine the range of knee motion

Timepoint

Before injection and 1, 3 and 6 months after the first injection

Method of measurement

Manual jointometry

Secondary outcomes

empty

Intervention groups

1

Description

Intervention group: In this group of patients, 10 ml of blood will be taken by PRP-specific syringe manufactured by Pishtaz Teb Zaman CO. and according to kit protocol, we will separate the PRP with reduced Leukocyte content. The PRP will then be injected by a physician into one of the two knees of the patient with knee osteoarthritis. The PRP injection volume will be 2 cc. The injection will be repeated twice with a 21 days apart.

Category

Treatment - Other

2

Description

Control group: Leukocyte-rich PRP will be Prepared and by the physician will be injected into another patient's knee. The PRP injection volume will be 2 cc. The injection will be repeated twice with a 21 days apart.

Category

Treatment - Other

Recruitment centers

1

Recruitment center

Name of recruitment center

Shahid Madani Hospital, Tabriz

Full name of responsible person

Mehdi Yousefi, Ph.D Of Medical Immunology

Street address

Shahid Madani Hospital, Golbad Avenue, Tabriz

City

Tabriz

Province

East Azarbaijan

Postal code

5166614766

Phone

+98 41 3335 7767

Email

mehdi_yusefi@yahoo.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Pishtaz Teb Zaman CO.

Full name of responsible person

Behrooz Hajeian Tehrani

Street address

Golha, Pishtaz Teb Zaman CO.

City

Tehran

Province

East Azarbaijan

Postal code

1494734463

Phone

+98 21 4219 7000

Email

mehdi_yusefi@yahoo.com

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Pishtaz Teb Zaman CO.

Proportion provided by this source

100

Public or private sector

Private

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Tabriz University of Medical Sciences

Full name of responsible person

Mehdi Yousefi

Position

Assistant Professor

Latest degree

Ph.D.

Other areas of specialty/work

Immunology

Street address

Tabriz University of Medical Sciences, Golgasht Avenue, Tabriz, Iran

City

Tabriz

Province

East Azarbaijan

Postal code

5166614766

Phone

+98 41 3336 4665

Fax

+98 41 3336 4665

Email

yousefime@tbzmed.ac.ir

Person responsible for scientific inquiries

Contact

Name of organization / entity

Tabriz University of Medical Sciences

Full name of responsible person

Mehdi Yousefi

Position

Assistant Professor

Latest degree

Ph.D.

Other areas of specialty/work

Immunology

Street address

Tabriz University of Medical Sciences, Golgasht Avenue, Tabriz, Iran

City

Tabriz

Province

East Azarbaijan

Postal code

5166614766

Phone

+98 41 3336 4665

Fax

+98 41 3336 4665

Email

yousefime@tbzmed.ac.ir

Person responsible for updating data

Contact

Name of organization / entity

Tabriz University of Medical Sciences

Full name of responsible person

Mehdi Yousefi

Position

Assistant Professor

Latest degree

Ph.D.

Other areas of specialty/work

Immunology

Street address

Tabriz University of Medical Sciences, Golgasht Avenue, Tabriz, Iran

City

Tabriz

Province

East Azarbaijan

Postal code

5166614766

Phone

+98 41 3336 4665

Fax

+98 41 3336 4665

Email

yousefime@tbzmed.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available